GlassScriptPhysician profile
Surabhi V Jong
NPI 1770088312
$4,411.00
in general payments reported to CMS, 2019-2025
24 companies · $1,508 in 2025
The $1,508 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $257 · 2023: $728 · 2024: $1,918 · 2025: $1,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,136 · Education: $17.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,136.03 |
| Education | $17.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,778.44 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $486.03 | 2024-2025 | |
| Glaxosmithkline, LLC. | $351.58 | 2023-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $295.11 | 2024-2025 | Orencia |
| Janssen Biotech, INC. | $286.07 | 2023-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $200.57 | 2023-2025 | Saphnelo |
| Amgen INC. | $178.97 | 2024-2025 | Tavneos, Otezla, Enbrel |
| Ucb, INC. | $173.90 | 2024-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $92.77 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $81.57 | 2024-2025 | Acthar |
| Genzyme Corporation | $79.31 | 2025 | |
| Alexion Pharmaceuticals, INC. | $53.41 | 2024 | Strensiq |
| Scilex Pharmaceuticals INC. | $52.47 | 2024 | |
| Ani Pharmaceuticals, INC. | $49.58 | 2024 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $45.93 | 2024 | Idacio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $37.17 | 2024-2025 | Hadlima |
| Kyowa Kirin, INC. | $36.63 | 2023-2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.23 | 2024 | Cyltezo |
| Genentech USA, INC. | $20.26 | 2024 | Actemra |
| Aurinia Pharma U.S., INC. | $18.84 | 2024 | Lupkynis |
| Celltrion USA INC. | $17.88 | 2023 | Yuflyma |
| Alvogen INC | $17.82 | 2025 | Teriparatide |
| Kiniksa Pharmaceuticals International, Plc | $17.37 | 2024 | Arcalyst |
| Depuy Synthes Sales INC. | $15.09 | 2024 | Orthovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surabhi Jong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.